SCHEMBL25883237

SCHEMBL25883237

C[C@H]1CC[C@H](CO)N(C(c2ccc(F)cc2)c2ccc(F)cc2)C1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DPP8 Q6V1X1 2/20 0.37
▸ DPP4 P27487 1/20 0.37
▸ DPP7 Q9UHL4 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ TRPA1 O75762 4/20 0.36
▸ OPRM1 P35372 1/20 0.36
▸ OPRD1 P41143 1/20 0.36
▸ OPRK1 P41145 1/20 0.36
▸ OPRL1 P41146 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.36
▸ POLB P06746 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ MAPT P10636 1/20 0.33
▸ TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25883200 1.00 DPP8 (0.37) DPP8DPP4DPP7ALDH1A1SMN1; SMN2
SCHEMBL25883475 0.87 SIGMAR1 (0.37) DPP8DPP4DPP7ALDH1A1SMN1; SMN2
SCHEMBL25883478 0.86 DPP8 (0.37) DPP8DPP4DPP7ALDH1A1SMN1; SMN2
SCHEMBL25883216 0.81 SIGMAR1 (0.36) DPP8DPP4DPP7ALDH1A1SMN1; SMN2
SCHEMBL25882229 0.80 SIGMAR1 (0.40) DPP8DPP4DPP7ALDH1A1SMN1; SMN2
SCHEMBL25882219 0.80 SIGMAR1 (0.40) DPP8DPP4DPP7ALDH1A1SMN1; SMN2
SCHEMBL25881984 0.80 SIGMAR1 (0.40) DPP8DPP4DPP7ALDH1A1SMN1; SMN2
SCHEMBL25881977 0.80 SIGMAR1 (0.40) DPP8DPP4DPP7ALDH1A1SMN1; SMN2
SCHEMBL25883462 0.80 MEN1 (0.38) ALDH1A1SMN1; SMN2TRPA1OPRM1POLB
SCHEMBL21910774 0.78 SIGMAR1 (0.45) DPP8OPRM1OPRD1OPRK1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG DPP8 3019/4885DPP4 3722/4885DPP7 3109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback